Biocompatible APTES-PEG modified magnetite nanoparticles: Effective carriers of antineoplastic agents to ovarian cancer

Applied Biochemistry and Biotechnology

Volumn 173, Issue 1, 2014, Pages 36-54

  Javid, Amaneh ^a   Ahmadian, Shahin ^a   Saboury, Ali Akbar ^a   Kalantar, Seyed Mehdi ^b   Rezaei Zarchi, Saeed ^c   Shahzad, Sughra ^d  

^a UNIVERSITY OF TEHRAN   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PAYAME NOOR UNIVERSITY   (Iran)

^d Social Security Hospital   (Pakistan)

Author keywords

Cytotoxicity; Encapsulation efficiency; Ovariancancer; PEGylation; Salination; Tumorvolume

Indexed keywords

BIODEGRADABLE POLYMERS; CYTOTOXICITY; DISEASES; DRUG DELIVERY; ENCAPSULATION; MAGNETITE NANOPARTICLES; NANOCOMPOSITES; SCANNING ELECTRON MICROSCOPY; SUPERPARAMAGNETISM; SYNTHESIS (CHEMICAL); TUMORS;

ENCAPSULATION EFFICIENCY; OVARIANCANCER; PEGYLATION; SALINATION; TUMORVOLUME;

BIOCOMPATIBILITY;

AMINO-PROPYL-TRIETHOXYSILANE; ANTINEOPLASTIC AGENT; BIOMATERIAL; DOXORUBICIN; DRUG CARRIER; MACROGOL DERIVATIVE; MAGNETITE NANOPARTICLE; SILANE DERIVATIVE;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; MOUSE; OVARIAN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; SILANES;

EID: 84905683374     PISSN: 02732289     EISSN: 15590291     Source Type: Journal    
DOI: 10.1007/s12010-014-0740-6     Document Type: Article

References (40)

1. 4 nanoparticles for a local hyperthermia agent in nanomedicine. Applied Physics Letters, 100, 092406.
2. 4-gold- chitosan nanostructure. Journal of Nanobiotechnology, 10, 3-9.
3. Cai, H., Xu, C., He, P., & Fang, Y. (2001). Nanoparticles: from theory to applications. Electroanalytical Chemistry, 510, 78-85.
4. Wu, W., & Jiang, X. (2012). Long-circulating polymeric drug nanocarriers. Functional nanoparticles for bioanalysis, nanomedicine, and bioelectronic devices. Volume 2, ACS Symposium Series, Vol. 1113, ISBN: 9780841228283, Chapter 2, pp 27-36. 4, 5.
5. Sun, C., Jerry, S., Lee, H., & Zhang, M. (2008). Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Delivery Reviews, 60, 1252-1265.
6. Neuberger, T., Schopf, B., Hofmann, H., Hofmann, H., & von Rechenberg, B. (2005). Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. Journal of Magnetism and Magnetic Materials, 293, 483-496.
7. Torchilin, V. P. (2006). Multifunctional nanocarriers. Advanced Drug Delivery Reviews, 58, 1532-1555.
8. 4 nanoparticles with daunorubicin induce apoptosis through caspase 8-PARP pathway and inhibit K562 leukemia cell-induced tumor growth in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 7, 595-603.
9. Biranwar, Y. A., Bare, K. R., Mahajan, V. R., Sapate, M. K., & Baviskar, D. T. (2011). Erythrocyte drug delivery system. International Journal of Pharmaceutical Science Review and Research, 8, 124-128.
10. Inui, O., Teramura, Y., & Iwata, H. (2010). Retention dynamics of amphiphilic polymers PEG-lipids and PVA-Alkyl on the cell surface. ACS Applied Material Interfaces, 2, 1514-1520.
11. Chao, Y., Su, A., Lin, Y., Hsu, W., & Huang, K. (2011). Synthesis and application of polyethylene glycol/vinyltriethoxy silane (PEG/VTES) copolymers. African Journal of Biotechnology, 10, 12754-12761.
12. Kitagawa, K., Kubota, K., Sueyoshi, K., & Otsuka, O. (2010). One-step preparation of amino-PEG modified poly(methyl methacrylate) microchips for electrophoretic separation of biomolecules. Journal of Pharmaceutical Biomedicine and Analysis, 53, 1272-1277.
13. Cole, A. J., David, A. E., Wang, J., Galbán, C. J., Hill, H. L., & Yang, V. C. (2011). Polyethylene glycol modified, cross-linked starch coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials, 32, 2183-2193.
14. 4 nanoparticles for reduced non-specific uptake by macrophage cells. Advanced Materials, 19, 3163-3166.
15. Zhang, Y., Kohler, N., & Zhang, M. (2002). Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials, 23, 1553-1561.
16. Yue-Jian, C., Juan, T., Fei, X., Jia-Bi, Z., Ning, G., & Yi-Hua, Z. (2010). Synthesis, self-assembly, and characterization of PEG-coated iron oxide nanoparticles as potential MRI contrast agent. Drug Development and Industrial Pharmacy, 36, 1235-1244.
17. Chen, Y. J., Tao, J., Xiong, F., Zhu, J. B., Gu, N., & Geng, K. K. (2010). Characterization and in vitro cellular uptake of PEG coated iron oxide nanoparticles as MRI contrast agent. Pharmazie, 65, 481-486.
18. Mikhayaylvo, M., Kim, D. K., & Berry, C. C. (2004). BSA immobilization on amine functionalized superparamagnetic iron oxide nanoparticles. Chemical Materials, 16, 2344-2354.
19. Naseri, G. M. (2012). The amounts of loaded DOX and PTX were 35 and 30.75 mg/g SPIO NPs. Carbohydrate Polymers, 90, 1265-1272.
20. Jain, K. K. (2005). The role of nanobiotechnology in drug discovery. Drug Discovery Today, 10, 1435-1442.
21. 4-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages. Beilstein Journal of Nanotechnology, 3, 444-455.
22. Mahmoudi, M., Simchi, A., Imani, M., Milani, A. S., & Stroeve, P. (2009). An in vitro study of bare and poly(ethylene glycol)-co-fumarate-coated superparamagnetic iron oxide nanoparticles: a new toxicity identification procedure. Nanotechnology, 20, 225104.
23. Fonseca, C., Simoes, S., & Gaspar, R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. Journal of Controlled Release, 82, 273-286.
24. Wang, Q., Zheng, X., Yang, L., Shi, Y., Gao, L., & Zhong, L. (2010). Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. Journal of Experimental and Clinical Cancer Research, 29, 159-167.
25. Lane, D., Côté, M.,&Grondin, R. (2006). Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Molecular Cancer Therapy, 5, 509-521.
26. Vanderhyden, B. C., Shaw, T. J., & Ethier, J. (2003). Animal models of ovarian cancer. Reproductive Biology and Endocrinology, 1, 67-77.
27. Ferrari, M. (2005). Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer, 5, 161-171.
28. Pardakhty, A., & Moazeni, E. (2013). Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomedicine Journal, 1, 1-13.
29. 4 magnetic nanoparticles modified with biocompatible copolymers. International Journal of Nanomedicine, 7, 144-156.
30. Brullot, W., Reddy, N. K., Wouters, J., Valev, V. K., Goderis, B., & Vermant, J. (2012). Versatile ferrofluids based on polyethylene glycol coated iron oxide nanoparticles. Journal of Magnetism and Magnetic Materials, 324, 1919-1925.
31. Gubin, S. P. (2009). Magnetic Nanoparticles. Hoboken: Wiley.
32. Sah, H. (1999). Stabilization of protein against methylene chloride water interface-induced denaturation and aggregation. Journal of Controlled Release, 58, 143-151.
33. Yoo, H. S., & Park, T. G. (2000). In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. Journal of Controlled Release, 68, 419-431.
34. Lu, A. H., Salabas, E. L., & Schuth, F. (2007). Magnetic nanoparticles: Synthesis, protection, functionalization, and application. Angewandte Chemie International Edition, 46, 1222-1244.
35. Wang, L. Y., Bai, J. W., Li, Y. J., & Huang, Y. (2008). Multifunctional nanoparticles displaying magnetization and near-IR absorption. Angewandte Chemie International Edition, 47, 2439-2442.
36. Hu, L., McArthur, C., & Jaffe, R. B. (2010). Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. British Journal of Cancer, 102, 1276-1283.
37. Tsuruta, Y., Mandai, M., & Konishi, I. (2001). Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. European Journal of Cancer, 37, 531-541.
38. Muscolini, M., Cianfrocca, R., & Sajeva, A. (2008). Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Molecular Cancer Therapeutics, 7, 1410-1419.
39. Villedieu, M., Louis, M. H., & Dutoit, S. (2007). Absence of Bcl-xL downregulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecologic Oncology, 105, 31-44.
40. Hine, C. M., Seluanov, A., & Gorbunova, V. (2012). Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer. Molecular Therapy, 20, 347-355.